

**Příloha č. 3: Publikace vztahující se k tématu disertace**

Příjmení, jméno, titul, učo:	Mladonická Pavlasová, Gabriela, Mgr., 321781
------------------------------	--

**Souhrn**

Publikace		Počet	IF/Q-WOS
Jimp	Prvoautorské	2	9.944/Q1 13.164/Q1
	Spoluautorské	2	9.944/Q1 16.601/Q1
Jrec	Prvoautorské	0	
	Spoluautorské	0	
Další	Knihy	0	
	Kapitoly v knize	0	
	Příspěvky ve sborníku	0	
	Jiné	33	

**Detailní přehled publikační aktivity**

**Originální práce s IF<sup>1</sup>**

**A. Prvoautorské**

1. Bibliografický záznam práce:<sup>2</sup> **Pavlasova G**, Borsky M, Seda V, Cerna K, Osickova J, Doubek M, Mayer J, Calogero R, Trbusek M, Pospisilova S, Davids MS, Kipps TJ, Brown JR, Mraz M. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. *Blood*. 2016 Sep 22;128(12):1609-13.

IF <sup>3</sup>	Q WOS	WOS kategorie
13.164	Q1	Hematology

**Citace (bibliografické záznamy citací)<sup>4</sup>**

1. Drennan S, Chiodin G, D'Avola A, Tracy I, Johnson PW, Trentin L, Steele AJ, Packham G, Stevenson FK, Forconi F. Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients. *Clin Cancer Res*. 2019 Apr 15;25(8):2503-2512.
2. Reiff SD, Muhowski EM, Guinn D, Lehman A, Fabian CA, Cheney C, Mantel R, Smith L, Johnson AJ, Young WB, Johnson AR, Liu L, Byrd JC, Woyach JA: Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. *Blood* 2018 132:1039-1049.
3. Palma M, Krstic A, Peña Perez L, Berglöf A, Meinke S, Wang Q, Blomberg KE, Kamali-Moghaddam M, Shen Q, Jaremko G, Lundin J, De Paepe A, Höglund P, Kimby E, Österborg A, Månsson R, Smith CI: Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes. *Br J Haematol* 2018, 183: 212-224.

<sup>1</sup> U publikací s IF (Impakt faktor) uvádějte i kategorii dle WOS a Q WOS (Impakt faktor kvartil), příklad: IF=1,167; GENETICS & HEREDITY Q4 (v případě více kategorií, uveďte kategorii s nejvyšším příslušným kvantilem).

<sup>2</sup> S ohledem na provádění následných kontrol dle nařízení/směrnic LF MU uvádějte při citování článků v případě více tvůrců všechny autory, NEPOUŽÍVEJTE zkratku „et al.“, „aj.“ (nebo ekvivalent v řeči, ve které je článek napsán).

<sup>3</sup> Uvádějte IF v roce publikování. Pokud je publikace zatím pouze přijata k tisku, uvádějte aktuální IF časopisu. Po schválení oborovou radou je možné uvádět i publikace před zahájením Ph.D. studia.

<sup>4</sup> Uvádějte jen nejvýznamnější citace. Je možné uvést i více citací než tři. Neuvádějí se autocitace, za autocitace se považuje i citace spoluautorů.

2. Bibliografický záznam práce: **Pavlasova G**, Borsky M, Svobodova V, Oppelt J, Cerna K, Novotna J, Seda V, Fojtova M, Fajkus J, Brychtova Y, Doubek M, Pospisilova S, Mayer J, Mraz M. Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels. *Leukemia*. 2018 Sep;32(9):2028-2031.

IF	Q WOS	WOS kategorie
9.944	Q1	Hematology

Citace (bibliografické záznamy citací)

1. Spunarova M, Tom N, Pavlova S, Mraz M, Brychtova Y, Doubek M, Panovska A, Skuhrova Francova H, Brzobohata A, Pospisilova S, Mayer J, Trbusek M. Impact of gene mutations and chromosomal aberrations on progression-free survival in hroniclymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience. *Leuk Res*. 2019 Jun;81:75-81.
2. Devan J, Janikova A, Mraz M. New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs. *Semin Oncol*. 2018 Oct;45(5-6):291-302.

## B. Spoluautorské

1. Bibliografický záznam práce: Cerna K., Oppelt J., Chochola V., Musilova K., Seda V., **Pavlasova G.**, Radova L., Arigoni M., Calogero R. A., Benes V., Trbusek M., Brychtova Y., Doubek M., Mayer J., Pospisilova S., Mraz M. MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells. *Leukemia*, 2019, 33(2): 403-414.

IF	Q WOS	WOS kategorie
9.944	Q1	Hematology

Citace (bibliografické záznamy citací)

1. Li Y, Mao M, Liu H, Wang X, Kou Z, Nie Y, Wang Y, Wang Z, Huang Q, Lang T, Gu Z, An L, Zhang X, Fu L. miR-34a and miR-29b as indicators for prognosis of treatment-free survival of chronic lymphocytic leukemia patients in Chinese Uygur and Han populations. *Mol Cell Probes*. 2019 Oct;47:101436.
2. Ren X, Engler-Chiurazzi EB, Russell AE, Sarkar SN, Rellick SL, Lewis S, Corbin D, Clapper J, Simpkins JW. MiR-34a and stroke: Assessment of non-modifiable biological risk factors in cerebral ischemia. *Neurochem Int*. 2019 Jul;127:73-79.
3. Wu W, Wu Z, Xia Y, Qin S, Li Y, Wu J, Liang J, Wang L, Zhu H, Fan L, Fu J, Xu W, Jin H, Li J. Downregulation of circ\_0132266 in chronic lymphocytic leukemia promoted cell viability through miR-337-3p/PML axis. *Aging (Albany NY)*. 2019 Jun 1;11(11):3561-3573.
2. Bibliografický záznam práce: Musilova K., Devan J., Cerna K., Seda V., **Pavlasova G.**, Sharma S., Oppelt J., Pytlik R., Prochazka V., Prouzova Z., Trbusek M., Zlamalikova L., Liskova K., Kruzova L., Jarosova M., Mareckova A., Kornauth C., Simonitsch-Klupp I., Schiefer A., Merkel O., Mocikova H., Burda P., Machova Polakova K., Kren L., Mayer J., Zent C. S., Trneny M., Evans A. G., Janikova A., Mraz M. miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels. *Blood*, 2018, 132(22): 2389-2400.

IF	Q WOS	WOS kategorie
16.601	Q1	Hematology

Citace (bibliografické záznamy citací)

1. Zhang N, Chen Y, Shen Y, Lou S, Deng J. Comprehensive analysis the potential biomarkers for the high-risk of childhood acute myeloid leukemia based on a competing endogenous RNA network. *Blood Cells Mol Dis*. 2019 Nov;79:102352.
2. Silva A, Bassim S, Sarkozy C, Mottok A, Lackraj T, Jurinovic V, Brodtkorb M, Lingjaerde OC, Sehn LH, Gascoyne RD, Weigert O, Steidl C, Kridel R. Convergence of risk prediction models in follicular lymphoma. *Haematologica*. 2019 Jun;104(6):e252-e255.

## Další publikace

Jiné

### Konferenční příspěvky v časopisech s IF:

Cerna K, Oppelt J, Radova L, Musilova K, Seda V, **Pavlasova G**, Jez M, Tom N, Pardy F, Malcikova J, Plevova K, Tichy B, Brychtova Y, Doubek M, Trbusek M, Mayer J, Koca J, Calogero R, Pospisilova S, Mraz M: MicroRNA involvement in DNA damage response and BCR signaling in malignant B cells. AACR Annual Meeting; Philadelphia, Pennsylvania (April 18-22, 2015); abstract no. 3084. *Cancer Res* (2015); 75 (15 Supplement): 3084-3084.

Musilova K, **Pavlasova G**, Cerna K, Seda V, Jez M, Brychtova Y, Doubek M, Mayer J, Arigoni M, Riccardo F, Calogero R, Pospisilova S, Kipps T, Janikova A, Mraz M: MicroRNA-150 influences microenvironmental interactions and prognosis of follicular lymphoma. ICML 2015: 13th International Conference on Malignant Lymphoma; Lugano, Switzerland (June 16-20); *Hematological Oncology* 2015: 33(S1): 100-180.

**Pavlasova G**, Borsky M, Seda V, Cerna K, Osickova J, Mayer J, Pospisilova S, Davids M S, Brown J R, Mraz M: Microenvironmental interactions up-regulate CD20 expression in CLL B cells, but confer resistance to rituximab. XVI International Workshop on Chronic Lymphocytic Leukemia 2015; Sydney, Australia (September 6-9); oral presentation; *Leukemia & Lymphoma* 2015: Abstracts from the XVI International Workshop on Chronic Lymphocytic Leukemia; 1-327. DOI:10.3109/10428194.2015.1080893.

**Pavlasova G**, Seda V, Borsky M, Cerna K, Osickova J, Mayer J, Pospisilova S, Davids M S, Brown J R, and Mraz M: Microenvironmental Interactions up-Regulate CD20 Expression in CLL B Cells through the CXCR4/SDF-1 Axis: Implications for CD20-Targeting Antibodies and the Use of BCRInhibitors in Combination. ASH 2015 Annual Meeting Abstracts, Orlando, Florida, USA (December 5-8). *Blood* Vol 126, Issue 23: 92-5599.

**Pavlasová G**, Borský M, Brown J, Pospíšilová Š, Mráz M: Interakce B lymfocytů s mikroprostředím vedou ke zvýšené expresi CD20 přes aktivaci dráhy CXCR4/SDF1: význam pro léčbu pacientů s B buněčnou leukémií. XVI. Mezioborové setkání mladých biologů, biochemiků a chemiků; Devět Skal Milovy, Czech Republic (May 10-12, 2016). *Czech Chemical Society Symposium Series* (2016); 14 (2): 80.

**Pavlasova G**, Borsky M, Seda V, Cerna K, Osickova J, Doubek M, Mayer J, Calogero R, Pospisilova S, M Davids M, Brown J, Mraz M: IBRUTINIB INHIBITS CD20 UP-REGULATION ON CLL B CELLS MEDIATED BY THE CXCR4/SDF-1 AXIS G. 21st Congress of the European Hematology Association; Denmark, Copenhagen (June 9-12, 2016); abstract no. p200; *Haematologica* (2016); 101(s1): 47.

**Pavlasova G**, Borsky M, Seda V, Cerna K, Osickova J, Doubek M, Brychtova Y, Mayer J, Pospisilova S, Davids MS, Brown JR, Mraz M: The expression of CD20 on malignant B cells is regulated by chemokine signaling through the CXCR4/SDF1 axis: implications for targeting the microenvironmental interactions. AACR Annual Meeting; New Orleans (April 16-20, 2016); abstract no. 3291. *Cancer Res* (2016); 76 (14 Supplement): 3291-3291.

Musilova K, **Pavlasova G**, Seda V, Vojackova E, Cerna K, Didi J, Pytlik R, Prochazka V, Prouzova Z, Zlamalikova L, Pospisilova S, Evans A, Zent CS, Kren L, Trneny M, Mayer J, Janikova A, Mraz M The Role of MicroRNA-150 in the Prognosis and Transformation of Follicular Lymphoma. 58th ASH Annual Meeting and Exposition (December 3-6, 2016); abstract no. 4125. Blood (2016); Vol 128, Issue 22: 92-5969 abstract no. 4125.

**Pavlasova G**, Borsky M, Musilova K, Seda V, Cerna K, Osickova J, Vojackova E, Brychtova Y, Doubek M, Pospisilova S, Mayer J and Mraz M: Rituximab Preferentially Eliminates BCR Signaling Proficient Chronic Lymphocytic Leukemia B Cells In Vivo. 58th ASH Annual Meeting and Exposition (December 3-6, 2016); abstract no. 2030. Blood (2016); Vol 128, Issue 22: 92-5969, abstract no. 2030.

**Pavlasova G**, Musilova K, Seda V, Cerna K, Vojackova E, Svobodova V, Mraz M: The identification of combinatorial therapeutic approaches with BCR inhibitors in B cell malignancies. In: Proceedings of the AACR Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer; Jan 4-7, 2017; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2017;16(10 Suppl):Abstract nr A34.

Cerna K, Oppelt J, Seda V, Musilova K, **Pavlasova G**, Mayer J, Pospisilova S, Mraz M: MicroRNA Induced by DNA Damage Response Regulate the Expression of FOXP1 and Therapy Response in CLL. XVII International Workshop on CLL, New York, USA (May 12-15, 2017); Leukemia and Lymphoma 2017: 58(S1): 73-74; Abstract ID 81.

Vojáčková E, Šeda V, Loja T, Černá K, Musilová K, **Pavlasová G**, Svobodová V, Sharma S, Mráz M. The role of microenvironment in the regulation of B-cell receptor signalling via modulation of GAB1 protein levels. XVII. Interdisciplinary Meeting of Young Biologists, Biochemists and Chemists; Devět Skal Milovy, Czech Republic (May 30- June 1, 2017) in Czech Chemical Society Symposium Series (2017); 15: 42-43.

Musilova K, **Pavlasova G**, Seda V, Cerna K, Vojackova E, Didi J, Pytlik R, Prochazka V, Prouzova Z, Zlamalikova L, Mocikova H, Jarosova M, Evans A, Zent C, Kren L, Trneny M, Mayer J, Janikova A, Mraz M: Down-regulation of miR-150 and up-regulation of its target FOXP1 is associated with transformation of follicular lymphoma. In 14th International Conference on Malignant Lymphoma (14-ICML); Lugano, Switzerland (June 14-17, 2017); Hematological Oncology 2017: 35(S1): 150-151; Abstract nr 142.

Musilova K, **Pavlasova G**, Seda V, Cerna K, Vojackova E, Didi J, Pytlik R, Prochazka V, Prouzova Z, Zlamalikova L, Mocikova H, Jarosova M, Evans A, Zent C, Kren L, Trneny M, Mayer J, Janikova A, Mraz M: Differential expression of microRNAs in transformation of follicular lymphoma to diffuse large B cell lymphoma. In AACR Annual Meeting, Washington, D.C., USA (Apr 1-5, 2017) in Proceedings of the 107th Annual Meeting of the American Association for Cancer Research 2017; 58: 380; Abstract nr 1479.

**Pavlasova G**, Borsky M, Svobodova V, Musilova K, Cerna K, Seda V, Osickova J, Brychtova Y, Doubek M, Pospisilova S, Mayer J, Mraz M: BCR signalling proficient chronic lymphocytic leukaemia cells are prone to rituximab mediated elimination in vivo. In 22nd EHA Annual Congress; Madrid, Spain (June 22-25, 2017); Haematologica 2017: 102(s2): 412-412; Abstract E1004.

**Pavlasova G**, Borsky M, Svobodova V, Oppelt J, Cerna K, Novotna J, Musilova K, Seda V, Vojackova E, Brychtova Y, Doubek M, Pospisilova S, Mayer J, Mraz M: CD20 supports BCR signaling in an intra-clonal aggressive chronic lymphocytic leukemia subpopulation of cells and rituximab primarily targets these BCR-proficient B cells in vivo. In AACR Annual Meeting, Chicago, Illinois, USA (Apr 14-18, 2018) in Proceedings of the Annual Meeting of the American Association for Cancer Research 2018;78(13 Suppl):Abstract nr 1012.

Ondrisova L, Seda V, Amruz Cerna K, **Pavlasova G**, Vojackova E, Oppelt J, Filip D, Sandova V,

Mayer J, Mraz M: Mechanism of leukemia cell adaptation to targeted therapy in chronic lymphocytic leukemia. XIX. Interdisciplinary meeting of young life scientists. Devět Skal Milovy, Czech Republic (May 20-23, 2019) in Czech Chemical Society Symposium Series (2019); 17: 27-28.

#### **Konferenční příspěvky:**

Seda V, Jez M, **Pavlasova G**, Cerna K, Musilova K, Pospisilova S, Doubek M, Brychtova Y, Mayer J, Mraz M: The effect of ZAP-70 on adaptor molecule involved in microenvironmental interactions of malignant B cells. CEITEC PhD Retreat; Valtice, Czech Republic (April 23- 24); abstract no. L41, p. 74.

Jez M, **Pavlasova G**, Cerna K, Musilova K, Seda V, Mayer J, Pospisilova S, Mraz M: Focal adhesion kinase regulation and expression in malignant B cells. CEITEC PhD Retreat; Valtice, Czech Republic (April 23-24); abstract no. L22, p. 55.

Musilova K, **Pavlasova G**, Didi J, Seda V, Cerna K, Jez M, Tom N, Brychtova Y, Doubek M, Mayer J, Arigoni M, Ricardo F, Calogero R, Pospisilova S, Kipps T, Janikova A, Mraz M: Microrna150 Influences Microenvironmental Interactions and Prognosis of B Cell Malignancies. ESH 2015: International Conference on The Tumour Microenvironment in the Haematological Malignancies and its Therapeutic Targeting; Lisbon, Portugal (May 7-9); abstract no. 3307.

Musilova K, **Pavlasova G**, Didi J, Seda V, Cerna K, Jez M, Tom N, Brychtova Y, Doubek M, Mayer J, Arigoni M, Ricardo F, Calogero R, Pospisilova S, Kipps T, Janikova A, Mraz M: Microrna150 Influences Microenvironmental Interactions and Prognosis of B Cell Malignancies. XXIX. Olomoucké hematologické dny; Olomouc, Czech Republic (May 31-June 1); oral presentation.

Cerna K, Oppelt J, Radova L, Musilova K, Seda V, **Pavlasova G**, Jez M, Tom N, Malcikova J, Tichy B, Brychtova Y, Doubek M, Trbusek M, Mayer J, Koca J, Arigoni M, Ricardo F, Calogero R, Pospisilova S, Mraz M: MicroRNAs in DNA damage response and BCR signaling in malignant B cell. Keystone Symposia on Molecular and Cellular Biology 2015: MicroRNAs and Noncoding RNAs in Cancer; Keystone, Colorado (June 7-12); abstract no. 2027.

**Pavlasová G**, Borský M, Šeda V, Černá K, Osičková J, Mayer J, Pospíšilová Š, Davids MS, Brown JR, Mráz M: Interakce buněk CLL s mikroprostředím vede ke zvýšené expresi CD20 přes chemokinovou dráhu CXCR4/SDF-1: Implikace pro léčbu anti-CD20 protilátkami a BCR-inhibitory. XVII. Slovensko-český hematologický transfuziologický zjazd, Bratislava, Slovakia (Sept 2015).

**Pavlasova G**, Borsky M, Seda V, Cerna K, Doubek M, Mayer J, Pospisilova S, Davids SM, Brown RJ, Mraz M: Ibrutinib inhibits CD20 up-regulation on CLL B cells mediated by the CXCR4/SDF-1 AXIS. Transfuzie a hematologie dnes (2016); 22(s): 24.

Mraz M, Cerna K, **Pavlasova G**, Musilova K, Seda V, Mayer J, Pospisilova S: MicroRNAs in the microenvironmental interactions of B cell leukemias. XXV. Biochemický sjezd, Praha, Czech Republic (September 13-16, 2016); abstract page 82.

**Pavlasová G**, Borský M, Brown JR, Mayer J, Mráz M: Expresie CD20 je regulována interakcí CLL buněk s mikroprostředím a rituximab preferenčně eliminuje maligní B buňky s vysoce aktivní signalizací přes B-buněčný receptor. 17. Pražský hematologický den, Praha, Czech Republic (October 13, 2016); abstract page 18.

Šeda V, Vojáčková E, Loja T, **Pavlasová G**, Černá K, Musilová K, Svobodová V, Sharma S, Mráz M. Regulation of B-cell receptor signalling in chronic lymphocytic leukaemia (CLL) microenvironment via modulation of GAB1 protein levels. CEITEC PHD RETREAT II, Telč, April 2017, p. 52.

Cerna K, Oppelt J, Seda V, Musilova K, **Pavlasova G**, Svobodova V, Mayer J, Pospisilova S, Mraz

M: MicroRNA Induced by DNA Damage Response Regulate the Expression of FOXP1 and Therapy Response in CLL. 2nd International Conference on the Long and the Short of Non-Coding RNAs, Heraklion, Greece (June 9-14, 2017); abstract no. 81, p.107.

Mraz M, Musilova K, Devan J, Cerna K, Seda V, **Pavlasova G**, Pytlik R, Prochazka V, Prouzova Z, Zlamalikova L, Liskova K, Kruzova L, Burda P, Machova Polakova K, Mocikova H, Kren L, Mayer J, Trneny M, Janikova A. MYC-mediated downregulation of miR-150 contributes to the transformation of follicular lymphoma to DLBCL by upregulating FOXP1 levels. In: XXXII. Olomoucké hematologické dny, Olomouc, April 2018, p.7-8.

**Pavlasova G**, Svobodova V, Borsky M, Oppelt J, Novotna J, Cerna K, Musilova K, Seda V, Brychtova Y, Doubek M, Pospisilova S, Mayer J, Mraz M: CD20 is a direct regulator of B-cell receptor signaling in the microenvironment of chronic lymphocytic leukemia. In: 23rd Congress of the European Hematology Association; 2018 June 14–17; Stockholm, Sweden: HemaSphere 2018; 2(S1): p490; Abstract PS1091.

Musilova K, Devan J, Cerna K, Seda V, **Pavlasova G**, Pytlik R, Prochazka V, Prouzova Z, Trbusek M, Zlamalikova L, Liskova K, Kruzova L, Jarosova M, Kornauth Ch, Simonitsch- Klupp I, Schiefer AI, Merkel O, Burda P, Machova Polakova K, Mocikova H, Kren L, Mayer J, Zent CS, Trneny M, Evans A, Janikova A, Mraz M: MYC-mediated downregulation of miR-150 contributes to the transformation of follicular lymphoma by upregulating FOXP1 levels. In: 23rd Congress of the European Hematology Association; 2018 June 14–17; Stockholm, Sweden: HemaSphere 2018; 2(S1): p269-270; Abstract PF634.

Mráz M, **Pavlasová G**, Svobodová V, Borský M, Oppelt J, Černá K, Musilová K, Šeda V, Brychtová Y, Doubek M, Pospíšilová Š, Mayer J: CD20 reguluje signalizaci přes B-buněčný receptor v mikroprostředí chronické lymfocytární leukémie. In: I. Český hematologický a transfuziologický sjezd, Praha, 2018 Sept 16-19, in Transfuze a hematologie dnes 2018; 24, Supplement 2, p. 5-6.

**Pavlasova G**, Sandova V, Borsky M, Oppelt J, Seda V, Brychtova Y, Pospisilova S, Doubek M, Mayer J, Mraz M: CD20 in the context of microenvironmental interactions of malignant B cells: Implications for targeted therapy. In: XXV. Pařízkovy dny, Ostrava 2019, March 6-8.

.....  
datum a podpis uchazeče